Award
National Cancer Institute 1P01CA302570-01
Project 1
Recipient
UNIVERSITY OF VIRGINIA
Award Amount
$399,645.00
Ceiling
$399,645.00
Awarded
August 14, 2025
Identifier
1P01CA302570-01
This project aims to improve AML treatment by targeting ceramide metabolism pathways, specifically CERK, to enhance cell death and overcome therapy resistance.
Description
Acute myeloid leukemia (AML) is the 2nd most common type of leukemia diagnosed with few significant improvements achieved over the past 40 years. The proposed study aims to target specific bioactive lipids to augment the efficacy of standard of care therapeutics, potentially impacting AML treatment.